Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.44
+5.2%
$2.37
$1.63
$6.15
$12.43M0.91288,060 shs53,960 shs
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$0.41
-1.2%
$0.54
$0.35
$4.90
$11.67M1.21878,840 shs149,968 shs
IN8bio, Inc. stock logo
INAB
IN8bio
$0.13
-2.9%
$0.18
$0.11
$1.74
$11.68M0.231.96 million shs2.65 million shs
NSTGQ
NanoString Technologies
$0.07
$0.07
$0.04
$5.18
$3.45M0.199.78 million shsN/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
-16.25%-18.60%+13.17%-18.31%-60.44%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
+3.75%0.00%-14.49%-69.49%+41,499,900.00%
IN8bio, Inc. stock logo
INAB
IN8bio
-9.68%-21.13%-18.81%-54.44%-88.27%
NSTGQ
NanoString Technologies
0.00%0.00%0.00%0.00%-42.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioCardia, Inc. stock logo
BCDA
BioCardia
2.7619 of 5 stars
3.83.00.00.01.62.50.6
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
1.4629 of 5 stars
3.50.00.00.00.01.70.6
IN8bio, Inc. stock logo
INAB
IN8bio
3.5851 of 5 stars
3.55.00.00.02.32.51.3
NSTGQ
NanoString Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCardia, Inc. stock logo
BCDA
BioCardia
3.50
Strong Buy$25.00924.59% Upside
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3.00
Buy$10.002,339.02% Upside
IN8bio, Inc. stock logo
INAB
IN8bio
3.00
Buy$6.004,562.00% Upside
NSTGQ
NanoString Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NSTGQ, BCDA, CLDI, and INAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/14/2025
IN8bio, Inc. stock logo
INAB
IN8bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $6.00
(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCardia, Inc. stock logo
BCDA
BioCardia
$58K214.30N/AN/A($1.11) per share-2.20
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$50K233.44N/AN/A($2.32) per share-0.18
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/A$0.58 per shareN/A
NSTGQ
NanoString Technologies
$127.26M0.03N/AN/A$0.98 per share0.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCardia, Inc. stock logo
BCDA
BioCardia
-$11.57M-$3.09N/AN/AN/A-1,999.77%N/A-208.38%N/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/A
IN8bio, Inc. stock logo
INAB
IN8bio
-$30.01M-$0.45N/AN/AN/AN/A-197.15%-130.48%N/A
NSTGQ
NanoString Technologies
-$159.54M-$3.53N/AN/A-102.44%N/A-53.79%N/A

Latest NSTGQ, BCDA, CLDI, and INAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.39-$0.59-$0.20-$0.59N/AN/A
5/8/2025Q1 2025
IN8bio, Inc. stock logo
INAB
IN8bio
-$0.06-$0.07-$0.01-$0.07N/AN/A
3/26/2025Q4 2024
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 million
3/13/2025Q4 2024
IN8bio, Inc. stock logo
INAB
IN8bio
-$0.07-$0.04+$0.03-$0.04N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/AN/AN/AN/AN/A
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/AN/A
NSTGQ
NanoString Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
1.78
1.78
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/A
0.19
0.19
IN8bio, Inc. stock logo
INAB
IN8bio
0.05
1.84
1.84
NSTGQ
NanoString Technologies
N/A
2.73
2.02

Institutional Ownership

CompanyInstitutional Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
12.53%
IN8bio, Inc. stock logo
INAB
IN8bio
92.05%
NSTGQ
NanoString Technologies
76.77%

Insider Ownership

CompanyInsider Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.00%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
24.28%
IN8bio, Inc. stock logo
INAB
IN8bio
15.50%
NSTGQ
NanoString Technologies
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
405.09 million3.67 millionOptionable
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3828.47 million20.04 millionN/A
IN8bio, Inc. stock logo
INAB
IN8bio
2090.77 million61.25 millionNot Optionable
NSTGQ
NanoString Technologies
55048.12 million46.63 millionOptionable

Recent News About These Companies

NanoString Technologies, Inc. (NSTGQ)
NanoString Technologies Inc (NSTGQ)

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCardia stock logo

BioCardia NASDAQ:BCDA

$2.44 +0.12 (+5.17%)
Closing price 04:00 PM Eastern
Extended Trading
$2.44 0.00 (-0.04%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Calidi Biotherapeutics stock logo

Calidi Biotherapeutics NYSE:CLDI

$0.41 -0.01 (-1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$0.42 +0.02 (+3.66%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

IN8bio stock logo

IN8bio NASDAQ:INAB

$0.13 0.00 (-2.87%)
Closing price 04:00 PM Eastern
Extended Trading
$0.13 0.00 (-1.32%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

NanoString Technologies NASDAQ:NSTGQ

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.